etoposide has been researched along with Critical Illness in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Burroni, B; Chapuis, N; Charpentier, J; Decroocq, J; Le Stang, V; Péju, E; Pène, F; Vigneron, C | 1 |
| Darmon, M; Fadllalah, J; Frapard, T; Mariotte, E; Valade, S | 1 |
| Bhattacharyya, R; Lee, JH; Ng, ZQ; Sultana, R; Tan, CJ | 1 |
| E, I; F, C; G, H; I, A; J, M; L, B; M, FR; M, LV; M, MB; M, U; P, D | 1 |
| Lovetrue, B | 1 |
| Janka, G; Machowicz, R; Wiktor-Jedrzejczak, W | 1 |
| Bayrakci, B; Carcillo, JA; Citak, A; Demirkol, D; Dursun, O; Erkek, N; Gedik, H; Karabocuoglu, M; Karapinar, B; Kendirli, T; Kesici, S; Koroglu, TF; Yildizdas, D | 1 |
1 review(s) available for etoposide and Critical Illness
| Article | Year |
|---|---|
Treatment and mortality of hemophagocytic lymphohistiocytosis in critically ill children: A systematic review and meta-analysis.
Topics: Child; Child, Preschool; Critical Illness; Etoposide; Humans; Immunoglobulins, Intravenous; Intensive Care Units, Pediatric; Lymphohistiocytosis, Hemophagocytic; Retrospective Studies | 2023 |
6 other study(ies) available for etoposide and Critical Illness
| Article | Year |
|---|---|
Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis.
Topics: Critical Illness; Etoposide; Hematologic Neoplasms; Humans; Lymphohistiocytosis, Hemophagocytic; Retrospective Studies | 2022 |
Acute circulatory failure in critically ill patients with hemophagocytic syndrome.
Topics: Adult; Critical Illness; Etoposide; Humans; Intensive Care Units; Lactates; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Norepinephrine; Retrospective Studies; Shock, Septic | 2022 |
Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients.
Topics: Adult; Aged; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Illness; Etoposide; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; Topoisomerase II Inhibitors | 2020 |
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients.
Topics: Comorbidity; COVID-19; COVID-19 Drug Treatment; Critical Illness; Disease Outbreaks; Disease Progression; Drug Discovery; Drug Therapy, Combination; Etoposide; Humans; Irinotecan; SARS-CoV-2; Sepsis; Signal Transduction; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Virus Internalization; Virus Replication | 2020 |
Your critical care patient may have HLH (hemophagocytic lymphohistiocytosis).
Topics: Critical Illness; Diagnosis, Differential; Etoposide; Humans; Intensive Care Units; Iron; Lymphohistiocytosis, Hemophagocytic; Topoisomerase II Inhibitors | 2016 |
Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Combined Modality Therapy; Critical Illness; Cyclosporine; Dexamethasone; Etoposide; Female; Ferritins; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Iron Overload; Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Male; Multiple Organ Failure; Plasma Exchange; Prednisolone; Regression Analysis; Sepsis; Survival Rate; Treatment Outcome; Turkey | 2012 |